军事医学2024，Vol.48Issue(11)：858-862,5.DOI:10.7644/j.issn.1674-9960.2024.11.010
血小板生成素受体激动剂罗米司亭治疗急性放射病研究进展
Research progress in the treatment of acute radiation sickness with thrombopoietin receptor agonist romiplostim
摘要
Abstract
Acute radiation sickness(ARS)is a systemic syndrome caused by exposure to large doses of radiation in a single or short period of time.Hematopoietic tissue injury is the basic injury in case of acute radiation sickness.Romiplostim(RP)is a thrombopoietin receptor agonist that promotes platelet production by stimulating bone marrow megakaryocytes.In recent years,studies have shown that RP has a significant effect on acute radiation sickness,and has been approved by the United States Food and Drug Administration(FDA)for the treatment of bone marrow acute radiation sickness.In this paper,the recent research progress in the treatment of acute radiation sickness with romiplostim is reviewed.关键词
罗米司亭/急性放射病/电离辐射/造血损伤Key words
romiplostim/acute radiation sickness/ionizing radiation/hematopoietic injury分类
医药卫生引用本文复制引用
杨馨,邢爽,余祖胤..血小板生成素受体激动剂罗米司亭治疗急性放射病研究进展[J].军事医学,2024,48(11):858-862,5.基金项目
国家自然科学基金项目(81202147) （81202147）
国家科技重大专项(2018ZX09J18103-003) （2018ZX09J18103-003）
